Skip to main content
SpringerLink
Log in

Immunogenicity of human interferon-beta-containing pharmaceuticals

  • Molecular and Cellular Mechanisms of Inflammation (Special Issue) Guest Editors S. A. Nedospasov and D. V. Kuprash
  • Published:
Biochemistry (Moscow) Aims and scope Submit manuscript

Abstract

Multiple sclerosis is a severe autoimmune disease with inflammatory component that continues to be resistant to treatment. One of the approaches retarding its progression is based on using nonspecific therapy with human interferon-beta (IFN-β)-containing pharmaceuticals. Neutralizing antibodies (NAbs) against genetically engineered pharmaceuticals developed by the patient’s immune system, which reduce their therapeutic and biological activity, pose a serious problem. Cell lines sensitive to IFN-β activity also quantifying NAb level are applied because direct measurement of IFN-β antiviral activity is complicated. This study was aimed at standardization and validation of a reporter cell system for measuring antihuman IFN-β NAb titers, and evaluation data were obtained with samples from 33 patients with multiple sclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

BTPs:

biotherapeutic products

IFN-β:

interferon-beta

LU:

laboratory unit

MS:

multiple sclerosis

NAbs:

neutralizing antibodies

RF:

rheumatoid factor

References

  1. Rader, R. (2008) Redefining biopharmaceutical, Nat. Biotechnol., 26, 743–751.

    Article  CAS  PubMed  Google Scholar 

  2. Baumann, A. (2006) Early development of therapeutic biologics–pharmacokinetics, Curr. Drug Metab., 7, 15–21.

    Article  CAS  PubMed  Google Scholar 

  3. Wadhwa, M., Knezevic, I., Kang, H. N., and Thorpe, R. (2015) Immunogenicity assessment of biotherapeutic products: an overview of assays and their utility, Biologicals, 43, 298–306.

    Article  CAS  PubMed  Google Scholar 

  4. WHO. Guidelines on clinical evaluation of vaccines: regulatory expectations (2004) WHO Tech Rep., 924, 35–102.

  5. Van Beers, M. M. C., and Bardor, M. (2012) Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins, Biotechnol. J., 7, 14731484.

    Google Scholar 

  6. Nazarov, V. D., Lapin, S. V., Surkova, E. A., Evdoshenko, E. P., Makshakov, G. S., and Totolian, A. A. (2015) Diagnostic and prognostic significance of intrathecal synthesis of immunoglobulin free light chains in multiple sclerosis, Med. Immunol. (Moscow), 17, 235–244.

    Article  Google Scholar 

  7. Nikfar, S., Rahimi, R., and Abdollahi, M. (2010) A metaanalysis of the efficacy and tolerability of interferon-ß in multiple sclerosis, overall and by drug and disease type, Clin. Ther., 32, 1871–1888.

    CAS  PubMed  Google Scholar 

  8. Govindappa, K., Sathish, J., Park, K., Kirkham, J., and Pirmohamed, M. (2015) Development of interferon betaneutralizing antibodies in multiple sclerosis–a systematic review and meta-analysis, Eur. J. Clin. Pharmacol., 71, 1287–1298.

    Article  CAS  PubMed  Google Scholar 

  9. Van Beers, M. M., Jiskoot, W., and Schellekens, H. (2010) On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis, J. Interf. Cytokine Res., 30, 767–775.

    Article  CAS  Google Scholar 

  10. Polman, C. H., Bertolotto, A., Deisenhammer, F., Giovannoni, G., Hartung, H. P., Hemmer, B., Killestein, J., McFarland, H. F., Oger, J., Pachner, A. R., Petkau, J., Reder, A. T., Reingold, S. C., Schellekens, H., and Sorensen, P. S. (2010) Recommendations for clinical use of data on neutralizing antibodies to interferon-beta therapy in multiple sclerosis, Lancet Neurol., 9, 740–750.

    Article  CAS  PubMed  Google Scholar 

  11. WHO Expert Committee on Biological Standardization. Thirty-fifth report (1985) World Health Organ. Tech. Rep. Ser., 725, 1–140.

  12. Deisenhammer, F. (2014) Interferon-beta: neutralizing antibodies, binding antibodies, pharmacokinetics and pharmacodynamics, and clinical outcomes, J. Interferon Cytokine Res., 34, 938–945.

    CAS  Google Scholar 

  13. Lam, R., Farrell, R., Aziz, T., Gibbs, E., Giovannoni, G., Großsberg, S., and Oger, J. (2008) Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNß in multiple sclerosis patients, J. Immunol. Methods, 336, 113–118.

    Article  CAS  PubMed  Google Scholar 

  14. Kawade, Y., Finter, N., and Grossberg, S. E. (2003) Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity, J. Immunol. Methods, 278, 127–144.

    Article  CAS  PubMed  Google Scholar 

  15. Meager, A., Dolman, C., Dilger, P., Bird, C., Giovannoni, G., Schellekens, H., Thorpe, R., and Wadhwa, M. (2011) An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products, J. Interferon Cytokine Res., 31, 383–392.

    Article  CAS  PubMed  Google Scholar 

  16. Gneiss, C., Tripp, P., Reichartseder, F., Egg, R., Ehling, R., Lutterotti, A., Khalil, M., Kuenz, B., Mayringer, I., Reindl, M., Berger, T., and Deisenhammer, F. (2006) Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients, Mult. Scler., 12, 731–737.

    Article  CAS  PubMed  Google Scholar 

  17. Roßs, C., Clemmesen, K. M., Sorensen, P. S., KochHenriksen, N., and Bendtzen, K. (2006) Measuring and evaluating interferon ß-induced antibodies in patients with multiple sclerosis, Mult. Scler., 12, 39–46.

    Article  Google Scholar 

  18. Manfredonia, F., Pasquali, L., Dardano, A., Iudice, A., Murri, L., and Monzani, F. (2008) Review of the clinical evidence for interferon ß 1a (Rebif) in the treatment of multiple sclerosis, Neuropsychiatr. Dis. Treat., 4, 321–336.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, 43, 655–661.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Molecular Medicine, Pavlov First Saint Petersburg State Medical University, 197022, St. Petersburg, Russia

    V. D. Nazarov, S. V. Lapin, A. V. Mazing & A. A. Totolian

  2. Saint-Petersburg Center of Multiple Sclerosis and Autoimmune Diseases Clinical Hospital No. 31, 197110, St. Petersburg, Russia

    E. P. Evdoshenko

  3. Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology (St. Petersburg Pasteur Institute), 197101, St. Petersburg, Russia

    A. A. Totolian

Authors
  1. V. D. Nazarov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. V. Lapin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. V. Mazing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. P. Evdoshenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. A. Totolian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. D. Nazarov.

Additional information

Original Russian Text © V. D. Nazarov, S. V. Lapin, A. V. Mazing, E. P. Evdoshenko, A. A. Totolian, 2016, published in Biokhimiya, 2016, Vol. 81, No. 11, pp. 1658–1664.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nazarov, V.D., Lapin, S.V., Mazing, A.V. et al. Immunogenicity of human interferon-beta-containing pharmaceuticals. Biochemistry Moscow 81, 1396–1400 (2016). https://doi.org/10.1134/S000629791611016X

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S000629791611016X

Keywords

Search

Navigation